Sterile liquid ampoules for injection, sterile liquid vials for injection, sterile liquid lyophilized vials for injection, and sterile liquid eye drops in PE bottles, sterile liquid diluent vials and vials containing sterile inhalation powder for nebulization by BFS (blow-fill-seal) technology can be manufactured in Kartepe sterile liquid drug manufacturing facilities.
In addition, with the new eye drop line established in 2019, preservative-free sterile liquid eye drops can also be produced.
In our facilities, in which 51.841,601 units of sterile liquid drugs were manufactured in 2018, a total of 42,3 million units were manufactured in 2019.
In our facility, in which a total of 35,65 million units of ampoules and 38,55 million solvent ampoules were manufactured in 2018, a total of 26,22 million units of ampoules and 32,87 million solvent ampoules were manufactured in 2019. The total number of single ampoules we manufactured in 2019 is 130 million.
On our production line for sterile liquid vials for injection and sterile liquid lyophilized vials for injection, on which a total of 12.13 million units of vials were manufactured in 2018, 11.2 million units of vials were manufactured in 2019.
On the BFS-SVP production line on which a total of 4,05 million units of production was achieved in 2018, about 4,05 million units in total were produced in 2019. A production increase of approximately 19% has been achieved compared to 2018.
Furthermore, in our facility, which was approved by the Ministry of Health, Ministry of Food, Agriculture and Livestock, and German Ministry of Health (for BFS-SVP production line), US FDA (by the United States Food and Drug Administration only for a sterile liquid vial and sterile liquid lyophilized vial production line) and Kenyan, Southern African, New Zealander (Medsafe), Portuguese (Infarmed) and Russian Health Authorities, inspections were carried out by the Ministry of Agriculture and Forestry, Infarmed (Portugal), Medsafe (New Zealand) and the Russian Health authorities and the notified body due to CE product certification by KIWA in 2019, and our facility successfully passed these inspections.
Our empty medical ampoule manufacturing unit meets a substantial part of the market’s need as one of the three leading medical ampoule manufacturing companies in our country.
Our facilities, which hold ISO 9001:2008 certificate, is audited by Thuringen on a periodical basis.
The number of empty ampoules we manufactured was 188,3 million in 2018, and 150,3 million in 2019.
In the unit where Boğaziçi Colognes, one of the bestselling brands in Turkey, are manufactured, products appealing to different sections of society such as 80º lemon cologne and lavender are being produced in line with Cosmetics GMP of T. C. The Ministry of Health.
Besides, our facilities, which hold ISO 9001:2008 certificate, is audited by TUV Thuringen on a periodical basis.
Our production numbers for colognes was 4,5 million in 2018 and 2,1 million in 2019. In Kartepe manufacturing facility, rate of capacity utilization was 93%.
The total human and veterinary products manufactured in our manufacturing facilities on a unit basis was 176.8 million units in 2016, 184.7 million units in 2017, 196.7 million units in 2018 and 200.7 million units in 2019.
The total manufacturing value (drugs and other) was realized as 359.6 million TL in 2016, 401.1 million TL in 2017, 541.4 million TL in 2018 and 687.6 million TL in 2019.